http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 주제어 : Idiopathic Pulmonary Fibrosis (검색결과 189 건)
- 무료
- 기관 내 무료
- 유료
-
( Yu Jin Kim ),( Seong Hyun Shin ),( Jeong Woong Park ),( Sun Young Kyung ),( Shin Myung Kang ),( Sang Pyo Lee ),( Yon Mi Sung ),( Yoon Kyung Kim ),( Sung Hwan Jeong ) 대한결핵 및 호흡기학회 2014 Tuberculosis and Respiratory Diseases Vol.77 No.1
Background: Combined pulmonary fibrosis and emphysema (CPFE) have different pulmonary function tests (PFTs) and outcomes than idiopathic pulmonary fibrosis (IPF). The intention of this study was to identify unknown differences between CPFE and IPF by a retrospective comparison of clinical data including baseline and annual changes in pulmonary function, comorbidities, laboratory findings, clinical characteristics and cause of hospitalization. Methods: This study retrospectively enrolled patients with CPFE and IPF who had undergone PFTs once or several times per year during a follow-up period of three years. Baseline clinical characteristics and the annual changes in the pulmonary function during the follow-up period were compared between 26 with CPFE and 42 patients with IPF. Results: The baseline ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC%) in patients with CPFE was lower than that in patients with IPF (78.6±1.7 vs. 82.9±1.1, p=0.041). The annual decrease in FEV1/FVC in the CPFE was significantly higher than in the IPF. The annual decreases in diffusion capacity of carbon monoxide and FVC showed no significant differences between the two groups. The symptom durations of cough and sputum were in the CPFE significantly lower than in the IPF. The serum erythrocyte sedimentation rate level at the acute stage was significantly higher than in the IPF. There were no significant differences in the hospitalization rate and pneumonia was the most common cause of hospitalization in both study groups. Conclusion: The annual decrease of FEV1/FVC was in patients with CPFE significantly higher than in the patients with IPF.
-
Kim, Yu Jin,Shin, Seong Hyun,Park, Jeong-Woong,Kyung, Sun Young,Kang, Shin Myung,Lee, Sang-Pyo,Sung, Yon Mi,Kim, Yoon Kyung,Jeong, Sung Hwan The Korean Academy of Tuberculosis and Respiratory 2014 Tuberculosis and Respiratory Diseases Vol.77 No.1
Background: Combined pulmonary fibrosis and emphysema (CPFE) have different pulmonary function tests (PFTs) and outcomes than idiopathic pulmonary fibrosis (IPF). The intention of this study was to identify unknown differences between CPFE and IPF by a retrospective comparison of clinical data including baseline and annual changes in pulmonary function, comorbidities, laboratory findings, clinical characteristics and cause of hospitalization. Methods: This study retrospectively enrolled patients with CPFE and IPF who had undergone PFTs once or several times per year during a follow-up period of three years. Baseline clinical characteristics and the annual changes in the pulmonary function during the follow-up period were compared between 26 with CPFE and 42 patients with IPF. Results: The baseline ratio of forced expiratory volume in one second to forced vital capacity ($FEV_1$/FVC%) in patients with CPFE was lower than that in patients with IPF ($78.6{\pm}1.7$ vs. $82.9{\pm}1.1$, p=0.041). The annual decrease in $FEV_1$/FVC in the CPFE was significantly higher than in the IPF. The annual decreases in diffusion capacity of carbon monoxide and FVC showed no significant differences between the two groups. The symptom durations of cough and sputum were in the CPFE significantly lower than in the IPF. The serum erythrocyte sedimentation rate level at the acute stage was significantly higher than in the IPF. There were no significant differences in the hospitalization rate and pneumonia was the most common cause of hospitalization in both study groups. Conclusion: The annual decrease of $FEV_1$/FVC was in patients with CPFE significantly higher than in the patients with IPF.
-
정성환,김유진,신성현,박정웅,경선영,강신명,이상표,성연미,김윤경 대한결핵및호흡기학회 2014 Tuberculosis and Respiratory Diseases Vol.77 No.1
Background: Combined pulmonary fibrosis and emphysema (CPFE) have different pulmonary function tests (PFTs) and outcomes than idiopathic pulmonary fibrosis (IPF). The intention of this study was to identify unknown differences between CPFE and IPF by a retrospective comparison of clinical data including baseline and annual changes in pulmonary function, comorbidities, laboratory findings, clinical characteristics and cause of hospitalization. Methods: This study retrospectively enrolled patients with CPFE and IPF who had undergone PFTs once or several times per year during a follow-up period of three years. Baseline clinical characteristics and the annual changes in the pulmonary function during the follow-up period were compared between 26 with CPFE and 42 patients with IPF. Results: The baseline ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC%) in patients with CPFE was lower than that in patients with IPF (78.6±1.7 vs. 82.9±1.1, p=0.041). The annual decrease in FEV1/FVC in the CPFE was significantly higher than in the IPF. The annual decreases in diffusion capacity of carbon monoxide and FVC showed no significant differences between the two groups. The symptom durations of cough and sputum were in the CPFE significantly lower than in the IPF. The serum erythrocyte sedimentation rate level at the acute stage was significantly higher than in the IPF. There were no significant differences in the hospitalization rate and pneumonia was the most common cause of hospitalization in both study groups. Conclusion: The annual decrease of FEV1/FVC was in patients with CPFE significantly higher than in the patients with IPF.
-
최원일 대한의사협회 2020 대한의사협회지 Vol.63 No.1
Idiopathic pulmonary fibrosis (IPF) is a condition that has been described as alveolar collapse and thickening, which correlate with dysregulated surfactant production and injury to type 2 alveolar cells. As resolution of chest computed tomography has improved, especially with the development of high-resolution computed tomography (HRCT), the diagnostic measures adopted for pulmonary fibrosis has gradually shifted from biopsy to HRCT. This shift towards HRCT has aided in diagnostic evaluation and detection of the therapeutic and adverse effects of drugs for pulmonary fibrosis. Further, after the endpoint was changed to forced vital capacity, significant improvements are being observed in clinical trial outcomes. Currently active clinical trials are replacing lung biopsy with HRCT. In 2014, pirfenidone and nintedanib gained approval for tandem use in patients with IPF. These drugs were found to not only reduce the progression of pulmonary fibrosis, but also the acute exacerbation and mortality associated with the condition. These drugs showed consistent benefits regardless of the severity of patients’ symptoms. Additionally, both nintedanib and pirfenidone were found to be effective in patients with advanced pulmonary fibrosis that was not classified as IPF. Nintedanib has been shown to reduce forced vital capacity in interstitial lung diseases associated with systemic sclerosis. In the next three to five years, many changes in treatment are expected, not only for IPF, but also for the entire spectrum of pulmonary fibrotic diseases. Pirfenidone and nintedanib are now considered standard treatments for IPF and few other fibrotic lung diseases. Clinicians treating patients with pulmonary fibrosis should keep themselves updated with the results of clinical trials that are currently underway.
-
( Hee-young Yoon ),( Sun-young Kim ),( Ok-jin Kim ),( Jin Woo Song ) 대한결핵 및 호흡기학회 2020 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.128 No.-
Background Air pollution affects clinical course and prognosis of idiopathic pulmonary fibrosis (IPF). However, the effect of individual exposure to air pollutant on disease progression (DP) in IPF is not well investigated. The purpose of our study was to evaluate impact of individual exposure to particulate matter with aerodynamic diameter ≤10 μm (PM10), and nitrogen dioxide (NO2) on DP in IPF patients. Methods Total 946 patients (mean age: 65.4 years, male: 80.9%) who were diagnosed with IPF at Asan Medical Center with serial lung function data were included in this study. Individual-level long-term concentrations to PM10 and NO2 at residential addresses of patients were estimated using a national-scaled exposure prediction model based on measurement concentration from regulatory monitoring sites. DP was defined as an absolute decline in forced vital capacity (FVC) ≥ 10%. Individual- (age, sex, the year at diagnosis, smoking status, lung function, treatment status) and area- (educational attainment, gross regional domestic product) level covariates were adjusted for our primary analysis model. Results Median follow-up period was 4.1 years (interquartile range: 2.1-6.9 years) and 547 patients (57.8%) experienced DP during follow-up. In the primary model, a 10 ppb increase in NO2 concentration was associated with a 10.5% increase in DP (hazard ratio [HR], 1.105 for 10 ppb; p=0.048) in patients with IPF (Figure 1A). There was an increasing trend of DP in patients with IPF according to the quartiles of NO2 (Q1: reference, Q2 [HR: 1.299, p=0.077], Q3 [HR: 1.409, p=0.050], Q4 [HR: 1.598, p=0.013]) (Figure 1B). PM10 was not associated with DP (HR, 1.030 for 10 μg/m3; p=0.547). Conclusions Our data suggest that increased individual exposure to NO2 can increase risk of in patients with IPF.
-
( Sang-eun Lee ),( Miae Kim ),( Sujin Moon ),( Gi-woon Hwang ),( Jin Woo Song ) 대한결핵 및 호흡기학회 2020 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.128 No.0
Background Stearoyl-CoA desaturase 1 (SCD1) is a key enzyme of lipogenesis that converts saturated fatty acid to monounsaturated fatty acid (MUFA) and polyunsaturated fatty acid (PUFA). Inhibition of SCD1 has been reported to have anti-tumor properties; however, the role of SCD1 in the pathogenesis of idiopathic pulmonary fibrosis (IPF) is not well defined. Methods Human lung tissues (IPF =10, control =10) were applied to Agilent 7890/5975 GC/MSD system and HP-5 MS column to analyze fatty acids of human specimens. MRC-5 cells (fibroblast cell line) treated with transforming growth factor-β1 (TGF-β1) was used as an in vitro model and C57BL/6 mouse treated with bleomycin as an in vivo model of pulmonary fibrosis. Protein levels in cell lysates or tissues were measured by Western blotting. Results Oleic acid, MUFA was elevated whereas stearic acid, saturated fatty acid was reduced in lung tissues from IPF patients compared with controls. Oleic acid up-regulated the protein expression levels of collagen typeⅠ and fibronectin in MRC-5 cells and human primary fibroblasts from patients. The protein expression of SCD1 was up-regulated in in vitro and in vivo IPF models. SCD1 inhibitor and SCD1 specific siRNA downregulated the TGF-β1 induced protein expression levels of collagen type I and fibronectin in MRC5 cells. Moreover, SCD1 inhibitor reduced phosphorylation of Smad2/3 in MRC-5 cells treated with TGF-β1. The hydroxyproline level, indicator of pulmonary fibrosis, in the lung tissues was also downregulated by the treatment with SCD1 inhibitor in bleomycin treated mice. Conclusions Our data showed that inhibition of SCD1 has anti-fibrotic effects on pulmonary fibrosis, suggesting that SCD1 is implicated as a potential therapeutic target of IPF.
-
리원연 ( Won Yeon Lee ) 대한결핵 및 호흡기학회 2009 Tuberculosis and Respiratory Diseases Vol.67 No.4
Interstitial lung disease (ILD) is a group of diseases characterized by pulmonary interstitial inflammation. Finally the inflammation results in pulmonary fibrosis and impairment of oxygen transportation. The causes of idiopathic interstitial pneumonia (IIP) are unknown. Diagnosis of IIP is not easy, especially distinguising between nonspecific interstitial pneumonia and usual interstitial pneumonia (UIP). First line treatments of IIP include corticosteroids and immune modulators, which have limited effect. Currently, several drugs are being researched to prevent and treat fibrosis. Newer drugs that may useful to treat pulmonary fibrosis include endothelin receptor antagonist, recombinant soluble TNF receptor antagonist, and cotrimoxazole. The causes of IIP are largely unknown, treatment is not specific, and prognosis is poor. Recent studies are underway to investigate the pathogenesis and treatment of IIP and pulmonary fibrosis. As the pathogenesis of IIP is elucidated, better treatments will emerge.
-
Ren Chen-Xi,Jin Xin,Xie Dan-Ping,Guo Xiao-Yu,Yu Li-Yun,Cui Yu-Dong,Kwon Taeho,Sun Hu-Nan 한국응용생명화학회 2021 Applied Biological Chemistry (Appl Biol Chem) Vol.64 No.5
Idiopathic pulmonary fibrosis (IPF) is a serious and irreversible chronic lung disease. Bleomycin (BLM) is an anticancer drug, which can cause severe lung toxicity. The main target of oxidative stress-induced lung injury is alveolar epithelial cells, which lead to interstitial fibrosis. The present study investigated whether hispidin (HP), which has excellent antioxidant activity, attenuates bleomycin-induced pulmonary fibrosis via anti-oxidative effects in A549 cells. We found that hispidin reduced bleomycin-induced fibrosis of A549 cells by reducing reactive oxygen species (ROS) levels and inhibiting epithelial-mesenchymal transition. Taken together, our data suggest that hispidin has therapeutic potential in preventing bleomycin-induced pulmonary fibrosis.
-
Choi, Moonhwan,Ban, Taehyun,Rhim, Taiyoun Korean Society for Molecular and Cellular Biology 2014 Molecules and cells Vol.37 No.2
Idiopathic pulmonary fibrosis (IPF) is the most common and severe type of idiopathic interstitial pneumonias (IIP), and which is currently no method was developed to restore normal structure and function. There are several reports on therapeutic effects of adult stem cell transplantations in animal models of pulmonary fibrosis. However, little is known about how mesenchymal stem cell (MSC) can repair the IPF. In this study, we try to provide the evidence to show that transplanted mesenchymal stem cells directly replace fibrosis with normal lung cells using IPF model mice. As results, transplanted MSC successfully integrated and differentiated into type II lung cell which express surfactant protein. In the other hand, we examine the therapeutic effects of microvesicle treatment, which were released from mesenchymal stem cells. Though the therapeutic effects of MV treatment is less than that of MSC treatment, MV treat-ment meaningfully reduced the symptom of IPF, such as collagen deposition and inflammation. These data suggest that stem cell transplantation may be an effective strategy for the treatment of pulmonary fibrosis via replacement and cytoprotective effect of microvesicle released from MSCs.
-
최문환,반태현,임태연 한국분자세포생물학회 2014 Molecules and cells Vol.37 No.2
Idiopathic pulmonary fibrosis (IPF) is the most common and severe type of idiopathic interstitial pneumonias (IIP), and which is currently no method was developed to restore normal structure and function. There are several reports on therapeutic effects of adult stem cell transplantations in animal models of pulmonary fibrosis. However, little is known about how mesenchymal stem cell (MSC) can repair the IPF. In this study, we try to provide the evidence to show that transplanted mesenchymal stem cells directly replace fibrosis with normal lung cells using IPF model mice. As results, transplanted MSC successfully integrated and differentiated into type II lung cell which express surfactant protein. In the other hand, we examine the therapeutic effects of microvesicle treatment, which were released from mesenchymal stem cells. Though the therapeutic effects of MV treatment is less than that of MSC treatment, MV treat-ment meaningfully reduced the symptom of IPF, such as collagen deposition and inflammation. These data suggest that stem cell transplantation may be an effective strategy for the treatment of pulmonary fibrosis via replacement and cytoprotective effect of microvesicle released from MSCs.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
